A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

NCT00782093 ↗

Phase 1 Completed 63 enrolled Ophthotech Corporation

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of volociximab intravitreous injection in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).

Timeline

Start: 2008-10
Primary completion: 2012-06
Completion: 2012-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Volociximab	Monoclonal antibody	—	Intravitreal

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

Summary

Timeline

Drugs

Indications